EBA
IONS icon

Eagle Bay Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Eagle Bay Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150
Closed -$6K – 1183
2021
Q3 		$6K Buy
150
+75
+100% +$2.83K ﹤0.01% 801
2021
Q2 		$3K Buy
+75
New +$2.94K ﹤0.01% 798

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Eagle Bay Advisors's IONS Position: Q4 2021 in Review

Eagle Bay Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2021, closing a stake of 150 shares — an estimated $6K sold.

Eagle Bay Advisors first reported a position in IONS in Q2 2021 and held it in 2 quarters. The position peaked at $6K in Q3 2021. 340 funds tracked by Wall St. Rank hold IONS as of Q4 2021.

  • Eagle Bay Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Eagle Bay Advisors sold 150 Ionis Pharmaceuticals shares in Q4 2021, an estimated $6K.
  • Eagle Bay Advisors first reported a position in Ionis Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Eagle Bay Advisors's Ionis Pharmaceuticals position peaked at $6K in Q3 2021.
  • 340 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2021.

Based on Eagle Bay Advisors's 13F filing for Q4 2021, filed 21 Jan 2022.